Pharyngeal adenoid cystic carcinoma

Summary

Pharyngeal adenoid cystic carcinoma (MONDO:0006367) is a cancer. A subtype of head and neck carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pharyngeal adenoid cystic carcinoma
Mondo ID	MONDO:0006367
NCIT	C5818
UMLS	C1335399
MedGen	233324
GARD	0024384
Is cancer (heuristic)	yes

Also known as: adenoid cystic carcinoma of pharynx · adenoid cystic carcinoma of the pharynx · pharyngeal adenoid cystic carcinoma · pharyngeal throat adenoid cystic cancer · pharynx adenoid cystic carcinoma

Disease family

This is a subtype of head and neck carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › pharyngeal adenoid cystic carcinoma

Related subtypes (15): eye carcinoma, external ear carcinoma, middle ear carcinoma, nasal cavity carcinoma, growth hormone-producing pituitary gland carcinoma, hypopharyngeal carcinoma, ameloblastic carcinoma, laryngeal small cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, pituitary adenocarcinoma, carcinoma of floor of mouth, lip and oral cavity carcinoma, oropharyngeal carcinoma, nasal cavity and paranasal sinus carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.